thalidomide has been researched along with 5-hydroxythalidomide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Iguchi, T; Inatsuki, S; Kizaki, M; Kobayashi, H; Miyachi, H; Noguchi, T; Oda, S | 1 |
| Hashimoto, Y; Katayama, R; Miyachi, H; Naito, M; Noguchi, T | 1 |
| Fujimoto, H; Hashimoto, Y; Miyachi, H; Miyajima, A; Noguchi, T; Sano, H | 1 |
| Hara, H; Matsunaga, N; Nakamura, S; Obata, T; Sasaki, T; Shibata, N; Sukeguchi, D; Takashima, M; Tanaka, M; Toru, T; Yamamoto, T | 1 |
| Chowdhury, G; Guengerich, FP; Igaya, S; Nakamura, M; Shibata, N; Shimizu, M; Suemizu, H; Yamazaki, H | 1 |
| Chowdhury, G; Guengerich, FP; Shibata, N; Yamazaki, H | 1 |
| Guengerich, FP; Horie, T; Kazuki, Y; Kuribayashi, S; Ninomiya, S; Oofusa, K; Shibata, N; Shimizu, M; Suemizu, H; Yamazaki, H | 1 |
| Arata, K; Guengerich, FP; Harada, T; Kazuki, Y; Murayama, N; Satoh, D; Shibata, N; Yamazaki, H | 1 |
| Asano, A; Furihata, H; Honda, T; Miyakawa, T; Miyauchi, Y; Sawasaki, T; Shibata, N; Tanokura, M; Yamanaka, S | 1 |
| Matsuoka, S; Nishida-Fukuda, H; Sawasaki, T; Shibata, N; Shoya, Y; Yamanaka, S | 1 |
| Abe, G; Iwasaki, T; Murai, H; Saito, D; Sawasaki, T; Shibata, N; Suzuki, T; Takahashi, H; Takeda, H; Tamura, K; Tokunaga, E; Yamanaka, S | 1 |
| Hasegawa, T; Kitajima, S; Kuwagata, M; Shimizu, M; Takashima, H; Yamazaki, H | 1 |
| Shimizu, M; Yamazaki, H | 1 |
13 other study(ies) available for thalidomide and 5-hydroxythalidomide
| Article | Year |
|---|---|
Tubulin-polymerization inhibitors derived from thalidomide.
Topics: Colchicine; Indoles; Isoindoles; Lactones; Macrolides; Nerve Tissue Proteins; Thalidomide; Time Factors; Tubulin; Tubulin Modulators | 2005 |
Cell differentiation inducers derived from thalidomide.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Screening Assays, Antitumor; Flow Cytometry; HL-60 Cells; Humans; Indoles; Isoindoles; Leukemia; Lipopolysaccharide Receptors; Structure-Activity Relationship; Thalidomide | 2005 |
Angiogenesis inhibitors derived from thalidomide.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Structure-Activity Relationship; Thalidomide; Umbilical Veins | 2005 |
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Drug Screening Assays, Antitumor; Humans; Hydrogen-Ion Concentration; Stereoisomerism; Thalidomide | 2009 |
In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
Topics: Animals; Chimera; Glutathione; Hepatocytes; Humans; Hydroxylation; Mice; Teratogens; Thalidomide | 2012 |
Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
Topics: Cytochrome P-450 Enzyme System; Humans; Kinetics; Molecular Structure; Oxidation-Reduction; Thalidomide | 2014 |
Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.
Topics: Animals; Cytochrome P-450 Enzyme System; Electrophoresis, Gel, Two-Dimensional; Hepatocytes; Humans; Mass Spectrometry; Mice; Protein Binding; Thalidomide | 2016 |
Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.
Topics: Cells, Cultured; Cytochrome P-450 CYP3A; Enzyme Induction; Female; Humans; Liver; Oxidation-Reduction; Placenta; Pregnancy; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger; Thalidomide | 2017 |
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; HEK293 Cells; Humans; Immunologic Factors; Protein Binding; Protein Domains; Stereoisomerism; Structural Homology, Protein; Substrate Specificity; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2020 |
An IMiD-induced SALL4 degron system for selective degradation of target proteins.
Topics: Cell Membrane; Gene Knockdown Techniques; HeLa Cells; Humans; Immunologic Factors; Proteolysis; Substrate Specificity; Thalidomide; Transcription Factor RelA; Transcription Factors; Transcriptional Elongation Factors; Ubiquitin-Protein Ligases | 2020 |
Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
Topics: Adaptor Proteins, Signal Transducing; Animals; Chick Embryo; Cytochrome P-450 CYP3A; Humans; Mice; Promyelocytic Leukemia Zinc Finger Protein; Proteolysis; Substrate Specificity; Teratogenesis; Teratogens; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2021 |
Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5'-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species.
Topics: Administration, Oral; Animals; Liver; Male; Mice; Rabbits; Thalidomide | 2021 |
Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes.
Topics: Animals; Coumarins; Cytochrome P-450 Enzyme System; Female; Humans; Microsomes, Liver; Oxidation-Reduction; Pregnancy; Rabbits; Rats; Species Specificity; Thalidomide | 2023 |